IRON DEXTRAN Drug Patent Profile

Which patents cover Iron Dextran, and when can generic versions of Iron Dextran launch?

Iron Dextran is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in IRON DEXTRAN is iron dextran. There are eighty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iron dextran profile page.

Summary for IRON DEXTRAN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for IRON DEXTRAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	IRON DEXTRAN	iron dextran	INJECTABLE;INJECTION	010787-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Iron Dextran: Market Landscape and Patent Strategy Analysis

Last updated: February 19, 2026

Iron dextran is an intravenous iron preparation used to treat iron deficiency anemia. This analysis examines the current market for iron dextran, key players, patent protections, and potential investment considerations.

What is the Current Market Size and Growth Projection for Iron Dextran?

The global iron dextran market was valued at approximately $850 million in 2023. Projections indicate a compound annual growth rate (CAGR) of 4.5% from 2024 to 2030, reaching an estimated $1.15 billion by the end of the forecast period. This growth is driven by increasing prevalence of iron deficiency anemia, particularly in developing economies, and the expanding use of intravenous iron therapies across various patient populations, including those with chronic kidney disease and inflammatory bowel disease [1].

Key Market Drivers:

• Rising Incidence of Iron Deficiency Anemia: Global estimates suggest iron deficiency anemia affects over 1.5 billion people, with significant prevalence in women of reproductive age and children [2].
• Advancements in Intravenous Iron Formulations: Development of more convenient and safer intravenous iron products, including higher-dose iron dextran formulations, contributes to market expansion.
• Increasing Diagnosis and Treatment Rates: Greater awareness and improved diagnostic capabilities lead to more patients receiving timely treatment with iron supplements.
• Off-Label Use Expansion: Iron dextran is increasingly used off-label for conditions not explicitly approved, further contributing to demand.

Market Restraints:

• Competition from Alternative Iron Therapies: Oral iron supplements, while less effective for severe deficiencies, remain a lower-cost alternative. Other intravenous iron formulations, such as ferric carboxymaltose and iron sucrose, offer direct competition.
• Potential for Allergic Reactions: Anaphylactic reactions, though rare with modern formulations, remain a concern and can limit widespread adoption in certain healthcare settings.
• Regulatory Hurdles and Pricing Pressures: Stringent regulatory approval processes and increasing pressure on healthcare costs can impact market access and profitability.

Who are the Dominant Players in the Iron Dextran Market?

The iron dextran market is characterized by a mix of established pharmaceutical companies and specialized manufacturers. Key players hold significant market share through a combination of product portfolios, manufacturing capabilities, and established distribution networks.

Major Manufacturers and Products:

• Fresenius Medical Care: A leading provider of dialysis products and services, Fresenius offers iron dextran products widely used in patients with chronic kidney disease. Their portfolio includes products like CosmoFer.
• Vifor Pharma (now part of CSL Vifor): Vifor Pharma has a strong presence in iron deficiency anemia treatment, offering various intravenous iron products. While their primary focus includes other IV iron types, they are a significant competitor in the broader IV iron space impacting iron dextran.
• American Regent, Inc. (a subsidiary of Daiichi Sankyo): American Regent manufactures and markets generic and branded injectable drugs, including iron dextran products. Their offerings are competitive in the generics space.
• Biotron Healthcare: This company focuses on the manufacturing and supply of pharmaceutical products, including iron dextran, often catering to emerging markets.

Competitive Landscape:

The market is moderately consolidated, with larger entities leveraging economies of scale. Competition exists across both branded and generic iron dextran formulations. Price is a significant factor, especially in markets where healthcare reimbursement is limited. Differentiation often occurs through delivery systems, product purity, and patient safety profiles.

What is the Patent Landscape for Iron Dextran?

The patent landscape for iron dextran is complex, reflecting the evolution of this therapy. While fundamental patents on the initial iron dextran complexes have long expired, innovation has focused on improvements in manufacturing processes, novel formulations, and methods of administration.

Key Patent Areas:

• Manufacturing Processes: Patents often cover specific methods for synthesizing the iron dextran complex, aiming for enhanced purity, controlled particle size, or improved stability. These processes can lead to higher yields and reduced impurities, which are critical for intravenous administration.
• Formulation Improvements: Research and development have focused on creating formulations with lower molecular weight iron dextran, potentially reducing the risk of hypersensitivity reactions. Patents may protect specific ratios of iron to dextran, pH adjustments, or the inclusion of excipients.
• Delivery Systems and Administration Methods: While less common, patents could exist for novel delivery devices or specific infusion protocols designed to optimize therapeutic delivery or minimize adverse events.
• Methods of Treatment: Patents might protect the use of iron dextran for specific patient populations or conditions where its efficacy has been further elucidated, such as in combination therapies or for specific anemia subtypes.

Expired and Expiring Patents:

The core patents for early iron dextran complexes and their basic use have long expired, paving the way for generic competition. However, patents on subsequent innovations continue to provide market exclusivity for specific formulations or manufacturing techniques. Companies continuously seek new patentable improvements to extend their intellectual property protection.

Example of a Patent Focus:

For instance, a patent might describe a method for producing a low molecular weight iron dextran by controlling the degree of dextran polymerization and the subsequent complexation with iron ions. Such a patent would protect the specific process, allowing the patent holder to exclusively manufacture or license this improved form of iron dextran.

What are the Regulatory Considerations for Iron Dextran Products?

Regulatory approval for iron dextran is critical for market access. Regulatory bodies evaluate the safety, efficacy, and quality of these products.

Key Regulatory Agencies:

• U.S. Food and Drug Administration (FDA): The FDA approves iron dextran products for marketing in the United States. Approval processes involve rigorous review of preclinical and clinical data.
• European Medicines Agency (EMA): The EMA oversees drug approvals in the European Union, employing a centralized procedure for marketing authorization.
• Other National Health Authorities: Bodies like Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA) have their own approval pathways.

Approval Pathways:

• New Drug Applications (NDAs): For novel iron dextran formulations or significant manufacturing changes.
• Abbreviated New Drug Applications (ANDAs): For generic versions of already approved iron dextran products, requiring demonstration of bioequivalence.

Post-Market Surveillance:

Regulatory agencies mandate pharmacovigilance activities to monitor adverse events and ensure ongoing product safety after market approval. This includes reporting of serious side effects, such as anaphylactic reactions, which are carefully scrutinized.

What are the Financials and Investment Outlook for Iron Dextran?

The financial performance of iron dextran manufacturers is influenced by market share, pricing strategies, and the cost of goods sold. For investors, the outlook depends on market growth, competitive intensity, and the strength of intellectual property.

Revenue Streams:

• Sales of Branded Products: Companies with patented, improved formulations can command higher prices.
• Sales of Generic Products: Generic manufacturers compete primarily on price and market penetration.
• Geographic Distribution: Sales volume varies significantly by region, influenced by healthcare infrastructure, anemia prevalence, and reimbursement policies.

Profitability Factors:

• Manufacturing Costs: The cost of raw materials (iron salts, dextran) and the complexity of the manufacturing process impact profit margins.
• Research and Development (R&D) Investment: Ongoing investment in improving formulations and manufacturing is necessary for long-term competitiveness.
• Marketing and Sales Expenses: Establishing and maintaining market presence requires significant expenditure.
• Reimbursement Rates: Payer policies for intravenous iron therapies directly affect revenue.

Investment Considerations:

• Market Growth Potential: The steady increase in diagnosed iron deficiency anemia and the expanding applications for IV iron suggest continued market growth.
• Competitive Dynamics: The presence of multiple players, including generic manufacturers, intensifies competition and can exert downward pressure on prices.
• Intellectual Property Strength: Companies with robust patent portfolios protecting innovative formulations or processes are better positioned for sustained profitability and market exclusivity.
• Regulatory Risk: Changes in regulatory requirements or post-market safety concerns can impact product availability and market access.
• Emerging Markets: These regions present significant growth opportunities due to high unmet needs but often come with higher risks related to infrastructure and pricing.

Key Takeaways

The iron dextran market is a stable segment within the pharmaceutical industry, driven by the persistent global burden of iron deficiency anemia. Growth is projected at a moderate CAGR, supported by increasing diagnosis rates and the expanding utility of intravenous iron therapies. The competitive landscape includes established pharmaceutical companies and generic manufacturers, with pricing and product differentiation being key market dynamics. While core patents have expired, innovation continues in manufacturing processes and formulation improvements, offering opportunities for companies to secure market exclusivity. Regulatory oversight is stringent, focusing on product safety and quality. Investment attractiveness hinges on market growth, competitive positioning, and the strength of intellectual property, with emerging markets offering significant but nuanced opportunities.

Frequently Asked Questions

1. What is the primary mechanism of action for iron dextran? Iron dextran is an intravenous iron preparation that replenches iron stores in the body. The iron is released from the dextran complex and binds to transferrin, which transports it to the bone marrow for hemoglobin synthesis.

2. What are the main side effects associated with iron dextran administration? Common side effects include temporary discoloration of the skin at the injection site, nausea, headache, and dizziness. Serious, though rare, side effects can include hypersensitivity reactions and anaphylaxis.

3. How does iron dextran compare to oral iron supplements in terms of efficacy? Iron dextran is generally more effective and faster-acting than oral iron supplements for treating moderate to severe iron deficiency anemia, especially in patients who cannot tolerate or absorb oral iron, or who require rapid iron replenishment.

4. Are there specific patient populations for whom iron dextran is particularly recommended? Iron dextran is often recommended for patients with significant iron deficiency anemia, those with chronic kidney disease undergoing dialysis, patients with inflammatory bowel disease, and individuals undergoing certain surgical procedures or chemotherapy who have poor oral iron absorption or tolerance.

5. What is the typical dosing strategy for iron dextran? Dosing is individualized based on the patient's degree of anemia, weight, and iron deficit. It is administered intravenously, either as a slow infusion or bolus injection, depending on the specific formulation and physician preference.

Citations

[1] Global Market Insights. (2023). Iron Dextran Market Size, Share & Trends Analysis Report By Product Type (High Molecular Weight, Low Molecular Weight), By Application (Iron Deficiency Anemia, Chronic Kidney Disease, Inflammatory Bowel Disease), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 – 2030. (Data for market size and projection derived from aggregated industry reports.)

[2] World Health Organization. (2021). Global prevalence of anaemia in 2021. Retrieved from https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia